A patent review of BRD4 inhibitors (2013-2019)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A patent review of BRD4 inhibitors (2013-2019)

Published:2019-12-13 Issue:1 Volume:30 Page:57-81
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Lu Tian¹²,Lu Wenchao²³⁴,Luo Cheng¹²³

Affiliation:

1. Department of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China

2. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

3. Department of Pharmacy, University of Chinese Academy of Sciences, Beijing, China

4. Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2020.1702645

Reference62 articles.

1. Epigenetic protein families: a new frontier for drug discovery

2. Selective inhibition of BET bromodomains

3. Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions

4. Bromodomain: an acetyl-lysine binding domain

5. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An updated patent review of BRD4 degraders;Expert Opinion on Therapeutic Patents;2024-09-04

2. Genome-wide identification, transcriptional analysis, and acetylated histone site recognition of the Bromodomain gene family in Pyropia yezoensis;Algal Research;2024-08

3. Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review);Oncology Reports;2024-04-12

4. Synthesis of 2-aryl quinoxaline derivatives and their in silico investigation for breast cancer medication;Synthetic Communications;2024-04

5. Pan‐cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours;Clinical and Translational Medicine;2024-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3